Alps Dx files to raise $3.25M seed for oral fluid drug testing
What's the deal? Alps DxDealroom has a profile for this one. Try Dealroom →, a diagnostics tooling and automation startup, has filed a notice with the US Securities and Exchange Commission (SEC) to raise up to $3,250,000 in a seed round. The Richmond, Virginia-based company launched in 2026 and is led by chief executive officer Ali Safavi.
What's the endgame? Alps Dx focuses on the speed, safety, and scalability of oral fluid drug testing and related pre-analytical workflows. Its platform handles end-to-end processing, from sample collection through pre-analytical testing.
Why now? The company says its mission is to help laboratories of all sizes adopt automation without requiring capital investments. It develops purpose-built instruments, consumables, and workflow software aimed at improving lab efficiency.
The SEC filing reflects a securities sale made under an exemption in Regulation D. Companies must file the notice within 15 days of the first sale.
The signal: At $3.25 million, the round sits in the middle of the pack for early-stage deals, a modest bet on a young company trying to modernize a niche corner of diagnostics.
Read more: intelligence360.news
Image credit: Alps Dx
